ClinicalTrials.gg
RecruitingNCT07193719ILOCOUpdated Oct 15, 2026

Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children

A Phase 1/2 interventional study of End-expiratory lung volume optimization maneuver with PEEP titration and Standard Care (in control arm) in Congenital Heart Disease, Cardiopulmonary Bypass and Cardiac Surgery, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Charite University, Berlin, Germany · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 15, 2026Study contact changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Heart Defects, Congenital with a site in Germany — 15 open to participants now, 15 under way, none of them phase 3. Heart Defects, Congenital · Germany.

Planned enrollment
9th of 24
80 · median 70
Started
2025
with 2 others
Phase 1/2
2 of 38
2 open now
Primary completion
2027-05
later than 4 of 14 live
Registered
33rd of 38
by date
Lead sponsor
5 of 38
Charite University, Berlin, Germany

Among the 38 studies in Heart Defects, Congenital with a site in Germany, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 4 of the 14 other live ones, and was the 33rd registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

15 of the 38 studies in Heart Defects, Congenital with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Heart Defects, Congenital with a site in Germany, or all of them as a file.
02

Study summary

The goal of this randomized interventional clinical trial is to learn if a standardized lung volume optimization maneuver (LVOM) is beneficial in

  1. study) children undergoing biventricular repair of their congenital heart disease (CHD) with cardiopulmonary bypass and
  2. study) in children with severe respiratory failure at risk for or need for ECMO.

The main questions it aims to answer are:

Main hypotheses of CHD study: Does a standardized PEEP-Titration maneuver, to optimize end-expiratory lung volume improve:

  • cardiac performance
  • lung function

Does it make a difference in:

  • length of ventilation
  • ventilation/perfusion mismatch of the lung
  • need for vasopressor support?

Main hypotheses of ECMO study:

Does a LVOM in children/infants with severe respiratory failure /ARDS

  • improve lung compliance and gas exchange
  • facilitate lung protective ventilation according to PALICC-2 guidelines
  • improve lung aeration and V/Q-matching assessed with EIT

Does it make a difference in

  • need for ECMO
  • duration of ECMO runs
  • hemodynamics stability
Read the detailed description

1) The objective of the CHD study is to define the impact of a LVOM after cardiac surgery with CPB on hemodynamics and lung mechanics in children with congenital heart disease (CHD) undergoing surgery.

The Specific Aims of this work are:

Specific Aim 1:

Evaluate hemodynamics and lung mechanics during and after a LVOM:

In cases of children undergoing cardiac surgery all measurements will be performed with closed chest conditions.

Specific Aim 2:

Evaluate a potential benefit of lung volume optimization by performing PEEP titration on hemodynamics and lung mechanics compared to standard care without PEEP titration to optimize end-expiratory lung volume while maintaining same tidal volume targets in cases and controls.

Hypotheses:

  1. Hemodynamics and lung mechanics will be significantly different before and after LVOM. We expect that there will be little difference between intervention and control group before performing PEEP titration in the interventional group.
  2. Once the PEEP titration has been performed in the interventional group, we hypothesize that patients who received the intervention will have improved hemodynamics and lung mechanics with modest PEEP while receiving the same tidal volume than the control group (U-shaped curves).

Rationale: Surgery with cardiopulmonary bypass typically involves an interruption of mechanical ventilation while CPB is running. This is oftentimes associated with atelectasis formation and impaired gas exchange due to reduced end-expiratory lung volume. While there have been few studies in adults that have shown that optimization of lung volume by performing PEEP titration after CPB can significantly improve Cardiac Index and right ventricular function, there have been only very few prospective pediatric studies which assessed the impact of different PEEP settings on hemodynamics, and lung mechanics after cardiac surgery in children. Because these patients are generally among the most fragile postoperative patients, it is critical to understand if specific ventilator strategies can help mitigate any negative hemodynamic consequences after surgery. The purpose of this study is to understand the critical cardiopulmonary interactions that occur with changes in lung volumes, and to determine optimal approaches to mechanical ventilation under these different circumstances.

Cardiopulmonary interactions differ based on the underlying cardiac anatomy and physiology. Most studies of cardiopulmonary interactions following surgery for congenital heart disease have examined the difference between positive and negative pressure ventilation. This work consistently showed improvement in cardiac output and pulmonary blood flow with negative pressure ventilation, while positive pressure ventilation was associated with decreased cardiac output. However, these studies have been conducted in the 1990's and positive pressure ventilation has changed significantly in the meantime.

Similarly, while patients with left ventricular dysfunction generally benefit from positive pressure ventilation, there is little data regarding the hemodynamic effects of positive pressure ventilation on right ventricular performance.

Modulating pulmonary vascular resistance by optimizing lung volumes might be a promising approach to improve both lung mechanics and hemodynamics. Studies in this population have focused more on the effects of FiO2 and hyperventilation than on respiratory mechanics and cardiopulmonary interactions.

2) The objective of the ECMO study is to evaluate if a LVOM in children and infants with ARDS at risk or need for ECMO has an impact on ECMO prevention or shortening of ECMO duration.

Specific aims:

  • assess the effect of LVOM on lung aeration and perfusion assessed with EIT
  • assess the effect of LVOM on hemodynamics with (primarily VV-ECMO) and without ECMO
  • evaluate if LVOM can prevent the need for ECMO
  • evaluate if LVOM can shorten ECMO duration

Rationale:

Children with NARDS or PARDS usually have reduced lung volumes. Typically ECMO is initiated when oxygenation index approaches 40 with further deterioration of hypercarbia, hemodynamics and worsening hypoxemia. Current treatment strategies include reducing ventilatory support on ECMO ("rest settings") which is typically followed by a "whiteout" of the lungs reflecting lung collapse and fluid infiltration. Usually within 10 days of ECMO support invasive ventilation is gradually increased to re-open the lung and allow for ECMO weaning. Optimizing lung volumes by performing a LVOM early on in the disease process might be beneficial to wean ECMO faster or even prevent its need by avoiding massive lung collapse during rest settings in patients that have high potential for lung recruitability.

03

Conditions studied

  • Congenital Heart Disease
  • Cardiopulmonary Bypass
  • Cardiac Surgery
  • Mechanical Ventilation
  • Positive End-expiratory Pressure (PEEP)
  • Lung Volume
  • Lung Mechanics
  • Hemodynamic Changes
  • Children
  • ARDS
  • ECMO

Keywords

  • cardiopulmonary interactions
  • end-expiratory lung volume
  • PEEP titration
  • ARDS
  • ECMO
  • cardiopulmonary bypass
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

CHD study:

Inclusion Criteria

  • congenital heart disease
  • surgery with cardiopulmonary bypass

Exclusion Criteria:

  • single ventricle physiology
  • ECMO/VAD
  • \<36weeks of gestational age
  • chronic lung disease
  • Endotracheal tube leak > 15%
  • lack of from parents.

ECMO study Inclusion Criteria

  • patients with respiratory failure on ECMO or at risk for ECMO
  • invasive ventilation

Exclusion Criteria:

- severe lung hypoplasia or interstitial lung disease

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    control

    CHD study: This group receives so called standard of care. This includes relatively low levels of PEEP (5cmH2O in case of planned surgery) and no standardized PEEP titration ECMO study: This group receives so called standard of care. This includes PEEP of 10cmH2O, peak inspiratory pressures of 20cmH2O and no standardized PEEP titration

    Procedure: Standard Care (in control arm)

  • Experimental
    treatment

    CHD study: This group receives an individual lung volume optimization maneuver with PEEP titration. PEEP titration is performed while monitoring lung mechanics to optimize end-expiratory lung volume and find final "best PEEP". ECMO study: This group receives an individual lung volume optimization maneuver with PEEP titration during conventional or CDP titration with high frequency oscillatory ventilation. PEEP/CDP titration is performed while monitoring lung mechanics and EIT indices to optimize end-expiratory lung volume and find final "best PEEP/CDP".

    Procedure: End-expiratory lung volume optimization maneuver with PEEP titration

Interventions

  • ProcedureEnd-expiratory lung volume optimization maneuver with PEEP titration

    CHD study: PEEP titration (incremental/decremental) will be performed to optimize lung volume and find levels of PEEP corresponding to the best lung compliance at the end of surgery. Typically PEEP levels between 10-20cmH2O will be applied based on individual response of patients' lung mechanics. Tidal volume will be kept constant at 6ml/kg in cases and controls. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate. ECMo study: PEEP/CDP titration (incremental/decremental) will be performed to optimize lung volume and find levels of PEEP/CDP corresponding to the best lung compliance, best match of overdistension and collapse and homogenization of tidal volume distribution (EIT) .

  • ProcedureStandard Care (in control arm)

    CHD study: Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O. No LVOM will be applied. ECMO study: patients will receive standard ECMO ventilation (PEEP 10cmH2O and PiP 20cmH2O) without performing LVOM

06

What researchers measure

Primary outcomes

  1. CHD study: Cardiac Index (L/min/BSA) 2. ECMO study: shortening of ECMO duration (Hours)

    CHD study: assessed by using POCUS ECMO study: time course (Hours)

    Time frame: perioperatively/periprocedurally

Secondary outcomes

  1. lung mechanics

    lung compliance (ml/cmH2O/kg)

    Time frame: perioperatively/periprocedurally

  2. right ventricular performance

    TAPSE PAAT Strain

    Time frame: perioperatively/periprocedurally

  3. Ventilation distribution

    EIT

    Time frame: perioperatively/periprocedurally

  4. Lung perfusion

    assessed with EIT (electrical impedance tomography)

    Time frame: perioperatively/periprocedurally

  5. dead space

    pulmonary dead-space fraction (Vd/Vt)

    Time frame: perioperatively/periprocedurally

  6. avDO2

    difference in arteriovenous oxygen content

    Time frame: perioperatively/periprocedurally

07

Study locations

1 of 1 sites recruiting
  • Unviersity of Tuebingen, PICU
    Tübingen, 72076, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 26, 2025
StartActual
Dec 5, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 20, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Unviersity of Tuebingen, PICU · Tübingen, Germany
Show 1 removed
  • German Heart Center of the Charité · Berlin, Germany
Oct 15, 2026
Contact
Study contact's phone or email changed: •••2800→•••4751. See the current contact
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • Unviersity of Tuebingen, PICU · Tübingen, Germany
    Show 1 removed
    • German Heart Center of the Charité · Berlin, Germany
    Contact Study contact's phone or email changed: •••2800→•••4751. See the current contact
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07193719
Responsible party
Jan Clausen, MD (Pediatric Cardiologist/Intensivist, University Hospital Tuebingen) — Principal investigator
First posted
Sep 26, 2025
Start date
Dec 5, 2025
Primary completion
May 31, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Jan C Clausen, MD
Contact
jan.clausen@posteo.de
004970712984751

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion